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In HIV-infected, combination antiretroviral therapy (cART)-treated patients, immune acti-
vation and microbial translocation persist and associate with inadequate CD4 recovery 
and morbidity/mortality. We analyzed whether alterations in the toll-like receptor (TLR) 
pathway could be responsible for the immune hyperactivation seen in these patients. 
PBMC/monocyte-derived macrophages (MDMs) of 28 HIV+ untreated and 35 cART-
treated patients with HIV-RNA < 40 cp/mL [20 Full Responders (FRs): CD4 ≥ 350; 15 
Immunological Non-Responders (INRs): CD4 < 350], as well as of 16 healthy controls 
were stimulated with a panel of TLR agonists. We measured: CD4/CD8/CD14/CD38/
HLA-DR/Ki67/AnnexinV/CD69/TLR4/8 (Flow Cytometry); PBMC expression of 84 TLR 
pathway genes (qPCR); PBMC/MDM cytokine release (Multiplex); and plasma lipopoly-
saccharide (LPS)/sCD14 (LAL/ELISA). PBMC/MDM from cART patients responded 
weakly to LPS stimulation but released high amounts of pro-inflammatory cytokines. 
MDM from these patients were characterized by a reduced expression of HLA-DR+ 
MDM and failed to expand activated HLA-DR+ CD38+ T-lymphocytes. PBMC/MDM 
from cART patients responded more robustly to ssRNA stimulation; this resulted in a 
significant expansion of activated CD38 +  CD8 and the release of amounts of pro- 
inflammatory cytokines comparable to those seen in untreated viremic patients. Despite 
greater constitutive TLR pathway gene expression, PBMC from INRs seemed to upregu-
late only type I IFN genes following TLR stimulation, whereas PBMC from full responders 
showed a broader response. Systemic exposure to microbial antigens drives immune 
activation during cART by triggering TLRs. Bacterial stimulation modifies MDM function/
pro-inflammatory profile in cART patients without affecting T-lymphocytes; this suggests 
translocating bacteria as selective stimulus to chronic innate activation during cART. 
High constitutive TLR activation is seen in patients lacking CD4 recovery, suggesting an 
exhausted immune milieu, anergic to further antigen encounters.
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inTrODUcTiOn
Virally effective combination antiretroviral therapy (cART) is char-
acterized by persistent immune hyperactivation, which has been 
proven a potent determinant of impaired immune recovery (1–4) 
and non-AIDS morbidity/mortality (5–9), urging the identification 
of causative pathways. Indeed, a convincing body of data has accu-
mulated that indicates immune activation not only as a consequence 
of viral-specific challenge but also as a reflection of bystander activa-
tion, resulting from innate immune responses (10, 11).
Microbial and viral components are known to trigger the 
innate immune response via toll-like receptor (TLR) signaling 
(12). In turn, TLR-driven cytokine production from monocytes/
macrophages and dendritic cells prompts T-cell activation, thus 
establishing the adaptive immune response (13–18). In untreated 
HIV infection, altered TLR expression and responsiveness have 
been described (19–21) and are only partially normalized by 
cART (21). Indeed, HIV-1 encodes for various TLR7/8 ligands 
that can mediate direct activation of the immune system in vitro 
(22–24). Likewise, HIV-driven gut barrier damage is not reverted 
by cART (25–28) and leads to the passage of microbial products 
in peripheral blood, mainly lipopolysaccharide (LPS), which is a 
TLR4 agonist (29, 30). Circulating LPS levels have been associ-
ated with immune activation both in treated and untreated HIV 
(31–35); furthermore, exogenous in  vivo LPS administration 
has been described to enhance immune activation (34). Besides, 
recent literature in both HIV-negative and HIV-positive indi-
viduals provided ex vivo evidence for a direct role of translocating 
microbial products in driving immune activation. In particular, 
ex vivo stimulation of PBMCs and antigen-presenting cells with 
bacterial ligands (including LPS), commensal bacteria, and 
combined bacterial and viral stimulus results in the production of 
pro- and anti-inflammatory cytokines (36–50). In cART-treated 
patients, increased CD8+ CD38+ cells have been reported upon 
LPS exposure in subjects with poor CD4+ T-cell restoration (50) 
as well as impaired IFN-α production, following stimulation of 
plasmacytoid dendritic cells with TLR7 and TLR9 agonists (51).
These data would altogether imply the testable hypothesis 
of TLR pathway as mediator of persistent immune activation/
inflammation upon effective cART. However, a thorough investi-
gation of the contribution of TLR pathway in sustaining immune 
activation in HIV+ patients on virologically suppressive cART as 
compared to both HIV+ untreated and uninfected individuals, 
and whether it might be associated to poor CD4 recovery on 
cART, has not been established yet.
To bridge this gap, we determined the effect of TLR challenge 
on downstream pathways in T-lymphocytes and monocytes/
macrophages from HIV-infected cART-untreated and treated 
individuals with different degrees of immune reconstitution who 




Sixty-three HIV-infected individuals were consecutively enrolled 
at the Clinic of Infectious Diseases and Tropical Medicine, ASST 
Santi Paolo e Carlo, University of Milan, Italy. Thirty-five patients 
were on stable cART for at least 12 months, with undetectable 
plasma HIV-RNA load (<40 cp/mL) in at least two consecutive 
assessments and CD4 nadir ≤350/mmc. Twenty-eight patients 
were antiretroviral naïve, with any CD4 count. Individuals 
with either signs/symptoms of gastrointestinal diseases or on 
antibiotic therapy at the time of study were excluded. HIV+ 
on cART were divided into two groups according to the degree 
of immune reconstitution following the introduction of cART: 
Full Responders (FRs, n  =  20) with CD4+ ≥350/mmc and 
Immunological Non-Responders (INRs, n  =  15) with CD4+ 
<350/mmc. We also enrolled 16 HIV-negative healthy subjects 
as controls.
All of the enrolled patients provided written informed consent 
according to the Ethical Committee of our Institution (Comitato 
Etico, ASST “Santi Paolo e Carlo”, Milan, Italy). The ethics com-
mittee specifically approved this study. All subjects gave written 
informed consent in accordance with the Declaration of Helsinki.
isolation and culturing of Primary 
Monocytes to Obtain Monocyte-Derived 
Macrophages
Monocytes from Ficoll-isolated PBMCs were separated from 
lymphocytes by adherence to tissue culture-treated plates (52). 
After 48 h of incubation, non-adherent cells were removed via 
two washes with warm RPMI. The purity of the monocytes 
was >90%, as determined by immunofluorescent staining with 
antiCD14 FITC antibody (BD Pharmigen, San Diego, CA, USA). 
The monocytes were differentiated into macrophages (MDMs) by 
culturing in RPMI medium supplemented with 10% fetal bovine 
serum, 2 mM glutamine, 100 U of penicillin/ml, and 100 µg of 
streptomycin/ml for 15 days prior to stimulation. The monocyte-
derived macrophages (MDMs) were washed with phosphate-
buffered saline (PBS), and the culture medium was replaced every 
2 days. After 15 days, the MDMs were removed by gently scraping 
with a plastic cell scraper and cold PBS.
stimulation of PBMcs and MDMs
Dose–response and timing curves were performed for each 
stimulus. Ficoll-separated PBMCs (4  ×  106  cells/well) and 
MDMs (5 × 105 cells/well) were stimulated for 24 h with LPS 
(50 µg/mL), peptidoglycan (PGN) (10 µg/mL), lipoteichoic acid 
(LTA) (1  µg/mL), ssRNA40, a uridine-rich ssRNA analog of 
HIV-1 ssRNA (6,25 µg/mL) (InvivoGen, San Diego, CA, USA), 
interferon-γ (IFNγ) (100  U/mL), anti-CD28 (1.25  µg/mL) 
(R&D System, Minneapolis, MN, USA), and anti-CD3 (2.5 µg/
mL) (BD Pharmigen, San Diego, CA, USA). After 24 h, the cells 
were harvested for flow cytometry analyses; the supernatants of 
a subset of 5 HIV−, 5 HIV+ untreated, and 11 HIV +  cART 
(5 INRs and 6 FRs) patients were collected and stored for the 
Luminex assay.
Flow cytometry
Cell-surface molecule expression of the cultured PBMCs and 
MDMs was evaluated by flow cytometry (FC500, Beckman 
Coulter) using the following fluorochrome-labeled antibodies: 
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CD4-PECy7, CD8-PECy5, CD14-PECy7, CD69-PECy5, 
CD45-PE, CD3-PECy7 (Beckman Coulter, Milan, Italy), 
CCR7-PE, CD45RA-FITC, HLA-DR-FITC, CD38-PE, CD4-PE, 
CD8-PerCPCy5.5, Ki67-FITC, CD14-FITC (BD Bioscience, San 
Diego, CA, USA), TLR-4-PE (R&D Systems, Minneapolis, MN, 
USA), and TLR-8-PE (Thermoscientific, Tema Ricerca, Milan, 
Italy). Activation (HLA-DR and CD38), apoptosis (Annexin V), 
proliferation (Ki67), maturation (CCR7/CD45RA), and TLR 
expression (TLR-4,-8) were determined from the total PBMC 
cultures. MDM activation and function markers were measured 
by the expression of CD69 and HLA-DR, respectively.
The following reagent combinations were used: CD8/CD4/
CD38/HLA-DR, CD4/AnnexinV/7AAD, CD8/AnnexinV/ 
7AAD, CD8/CD4/Ki67, CD45RA/CCR7/CD4/CD8, CD45/
CD14/CD69/HLA-DR, CD3/CD14/TLR4, and CD3/CD14/
TLR8. CXP software from Beckman Coulter was used for the 
analyses. PBMCs were gated first based on side- and forward-
scatter properties, then as CD4+ or CD8+ and finally as CD38/
HLA-DR or Annexin V/7AAD or Ki67 or CCR7/CD45RA. To 
measure TLR expression, PBMCs were first gated based on side- 
and forward-scatter properties, then as CD3/CD14 and, within 
the CD14+ gate, cells were gated as TLR4+ or TLR8+. MDMs 
were gated first based on side-scatter properties and CD45+, then 
as CD14+, and finally as CD69/HLA-DR.
Microbial Translocation Markers
Plasma levels of sCD14 and LPS were measured by an ELISA 
assay (R&D Systems, Minneapolis, MN, USA) and the LAL test 
(Kinetic-QCL; Bio Whittaker, Walkersville, MD, USA), respec-
tively, and used according to the manufacturer’s instructions.
hiV-rna Quantification
Plasma HIV-RNA was quantified using the Abbott RealTime 
HIV-1 assay, with a detection limit of 40 cp/ml, according to man-
ufacturer’s instruction. The HIV-RNA copy numbers between 0 
and 40 (low-level residual viremia) were extrapolated from the 
standard curve of the assay (Abbott Laboratories, Princeton, NJ, 
USA).
Multiplex assays
The relative contents of 25 analytes in culture supernatants 
of a subset of 11 HIV+ cART-treated subjects (5 INRs and 6 
FRs) were determined using the human Th17 Magnetic Bead 
Panel (EMD Millipore; Billerica, MA, USA) with a Bio-Plex® 
MAGPIX™ Multiplex Reader (Bio-Rad Laboratories, Hercules, 
CA, USA), according to the manufacturer’s instructions. The rela-
tive content of 12 analytes in culture supernatants of a subset of 
five HIV + naïve subjects and five HIV-negative healthy controls 
was quantified using Luminex Screening Assay (R&D Systems, 
Minneapolis, MN, USA) with a Bio-Plex® MAGPIX™ Multiplex 
Reader (Bio-Rad Laboratories, Hercules, CA, USA). All samples 
were run in duplicate. The raw data were analyzed using Bio-
Plex Manager software. Standard curves were generated from 
lyophilized standards provided with each kit. The concentration 
for each analyte in each sample was determined via interpolation 
from each corresponding standard curve.
rna extraction and reverse Transcription
RNA was extracted from cultured PBMCs using the acid guan-
idium thiocyanate–phenol–chloroform method. RNA was puri-
fied from genomic DNA with RNase-free DNase (RQ1 DNase, 
Promega, Madison, WI, USA). Then, 1 µg of RNA was reverse 
transcribed into first-strand cDNA in a 20-µL final volume 
containing 1 µM random hexanucleotide primers, 1 µM oligo dT, 
and 200 U Moloney murine leukemia virus reverse transcriptase 
(Clontech, Palo Alto, CA, USA).
Tlr signaling Pathway
The TLR signaling pathway was analyzed in a PCR array that 
include a set of 84 optimized real-time PCR primers plus five 
housekeeping genes on a 96-well plates; the procedures suggested 
by the manufacturer were followed (SABiosciences Corporation, 
Frederick, MD, USA). Controls for genomic DNA contamination, 
RNA quality, and general PCR performance were also included 
on each array. The experiments were run on all HIV-negative 
healthy controls, HIV +  untreated, and cART (INRs and FRs) 
subjects included in the study and pooled into unique HIV-
negative, untreated HIV+, HIV + cART (INRs and FRs) samples, 
respectively (53). Thus, the results represent the mean value of 
the different targets analyzed in the study groups. Furthermore, 
the targets with marked differences between groups were retested 
by real-time PCR on each individual sample to confirm the data 
obtained in the array (data not shown).
statistical analysis
All continuous variables are presented as medians and interquar-
tile ranges (25th–75th percentile), whereas categorical data are 
shown as absolute numbers and percentages. Chi- squared or 
Fisher’s Exact test was used for the analyses of categorical vari-
ables. Mann–Whitney U test, Wilcoxon test, and Kruskal–Wallis 
test were used for the comparison of immunological parameters 
between the study groups. Correction for multiple comparisons 
was performed by post hoc analysis (Bonferroni or Dunn test). 
p-Values < 0.05 were considered significant. Statistical analyses 
and graphs were performed using GraphPad Prism 5 software.
resUlTs
study Population characteristics
The epidemiological, clinical, and immunological characteristics 
of the HIV-infected study groups and HIV-uninfected healthy 
controls are listed in Table  1. While all cART patients had an 
HIV-RNA <  40  cp/ml (as per inclusion criteria), median HIV 
low-level residual viremia was 20 cp/ml (IQR: 15–22). As shown 
in Table 1, cART patients featured lower CD4 nadir (p < 0.0001) 
and CD4 count at time of analysis (p = 0.003), displayed higher 
proportion of AIDS diagnosis (p = 0.003) and longer HIV infec-
tion (p < 0.0001).
Increased microbial translocation with HIV infection is 
evident as both cART and untreated HIV+ subject groups 
have, on average, higher LPS/sCD14 levels in the plasma than 
HIV-uninfected controls (LPS: p = 0.0045; sCD14: p = 0.0002). 
Furthermore, both HIV+ untreated and cART patients have 
TaBle 1 | epidemiological, clinical, and immunological characteristics of the study groups.
hiV-negative (n = 16) hiV+ untreated (n = 28) hiV+ carT (n = 35) p-Value
Age, years (IQR)a 31 (28–35) 34 (29–39) 48 (41–64) <0.0001
Sex (%)b <0.0001
Female 11 (69) 3 (11) 7 (20)
Risk factors (%)b <0.0001
Heterosex 13 (81) 6 (21) 18 (51)
Homosex/bisex 3 (19) 22 (79) 11 (31)
IDU 0 (0) 0 (0) 6 (18)
HCV co-infection (%)b 0.231
Yes 0(0) 2 (7) 5 (14)
AIDS diagnosisb (%) (yes) N/A 2 (7) 14 (40) 0.003
Time since first HIV Ab+ test, years (IQR)a N/A 2 (2–4) 5 (4–7) <0.0001
CD4 T-cell count (IQR)a
Nadir (n) N/A 400 (324–524) 94 (26–217) <0.0001
Time of analysis (n) 521 (413–592) 372 (253–455) 0.003
HIV-RNA Log cp/mL (IQR)a at time of analysis N/A 4.39 (3.74–5.12) 1.59 (1.59–1.59) <0.0001
Low-level residual viremia HIV-RNA (cp/ml) N/A N/A 20 (15–22) N/A
cART duration, years (IQR)a N/A N/A 5 (3–6) N/A
cART regimen (%)b
NRTI + PI N/A 24 (68.5) N/A
NRTI + NNRTI N/A 8 (23)
Others 3 (8.5)
TLR4+ CD14+ (%) (IQR) 98.6 (97–99) 89.3 (47–99) 78 (57–87) 0.002
TLR8+ CD14+ (%) (IQR) 99.8 (99.7–100) 99.4 (97–100) 90.2 (84–96) 0.001
LPS, pg/ml (IQR) 75 (75–81) 187 (97–427) 203 (83–258) 0.0045
sCD14, μg/ml (IQR) 1.96 (1.39–2.10) 3.32 (2.81–5.14) 5.61 (3.25–7.92) 0.0002
CD45RA+ CCR7+ CD4+ (%) (IQR) 49.9 (2.4–57.4) 2.1 (1.1–22.7) 2.6 (1.9–8.8) 0.102
CD45RA− CCR7+ CD4+ (%) (IQR) 18.1 (3.6–23.2) 3.4 (2.1–8.1) 2.77 (1.7–11.7) 0.035
CD45RA− CCR7− CD4+ (%) (IQR) 21.1 (12.2–54.7) 48.6 (33.8–58.7) 45.4 (27.1–66.3) 0.242
CD45RA+ CCR7− CD4+ (%) (IQR) 5.8 (3.4–31.3) 36.6 (22.4–55.9) 32.3 (22.1–49.6) 0.026
CD45RA+ CCR7+ CD8+ (%) (IQR) 23.4 (12.9–24.6) 12.3 (4.5–46.1) 6.5 (2.6–17.9) 0.254
CD45RA− CCR7+ CD8+ (%) (IQR) 1.3 (1.1–2.2) 1.3 (0.6–7.3) 2.1 (0.8–5.7) 0.376
CD45RA− CCR7− CD8+ (%) (IQR) 25.1 (18.9–36.7) 49.1 (19.1–51.7) 36.2 (18.7–58.3) 0.494
CD45RA+ CCR7− CD8+ (%) (IQR) 43.1 (39.1–59.1) 35.4 (27.6–44.3) 42.9 (27.5–56.9) 0.727
aData are median (IQR). IQR, interquartile range; statistical analyses: Mann–Whitney U Test or Kruskall–Wallis with Dunn’s Multiple Comparison test.
bData are n (%), statistical analyses: Pearson chi squared or Fisher exact test; p values are referred to the comparison between the three study groups where applicable.
cART, combination of antiretroviral therapy; IDU, intravenous drug users; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; NNRTI, non-nucleoside reverse 
transcriptase inhibitor; LPS, lipopolysaccharide; TLR, toll-like receptors.
Statistically significant p values (p < 0.05) are highlighted in bold font.
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skewed CD4 T-cell immune phenotypes, with lower frequencies 
of central memory (p = 0.035) and higher frequencies of termi-
nally differentiated (TD) CD4+ T cells (p = 0.026) as compared 
to healthy controls.
Table  2 summarizes the characteristics of HIV+  cART 
individuals, which were stratified into two groups FRs (n = 20) 
and INRs (n = 15) according to the degree of immune recovery. 
Patients were comparable for all epidemiological and immuno-
logical features. No differences in T-cell maturation phenotypes 
and microbial translocation markers were found between the 
groups (Table 2).
effect of Tlr stimulation on PBMc
We first investigated possible differences in the response of 
PBMC to TLR stimulation in HIV-infected untreated and treated 
patients versus uninfected controls.
In Vitro TLR Challenge on PBMCs: T Cell Activation, 
Proliferation, and Apoptosis
The effect of TLR stimulation on T cell activation, proliferation, 
and apoptosis was first determined. Interestingly, while the 
frequencies of activated HLA-DR+ CD4 and CD38 + CD8, pro-
liferating Ki67+ and pro-apoptotic Annexin V + CD4, and CD8 
T-cell subpopulations were not affected by bacterial stimulation 
in all study groups (Figures 1A–F), activated CD38 + CD8 T-cells 
were expanded by viral stimulation uniquely in cART-treated 
patients who reached significantly higher proportions than the 
other groups (ssRNA p = 0.044; Figure 1B).
The levels of activated HLA-DR+ CD4 and CD38 +  CD8 
T-cells (Figures 2A,B), proliferating Ki67+ (Figures 2C–E), and 
apoptotic Annexin V + CD4 and CD8 T-cells (Figures 2F,G) after 
TLR stimulation were similar between the FRs and INRs among 
the cART subjects.
TaBle 2 | epidemiological, clinical, and immunological characteristics of the study groups.
Frs (n = 20) inrs (n = 15) p-Value
Age, years (IQR)a 51 (41–68) 45 (39–54) 0.278
Sex (%)b
Female 6 (30) 1 (7) 0.198
Risk factors (%)b 0.271
Heterosex 11 (55) 7 (47)
Homosex/bisex 6 (30) 5 (33)
IDU 3 (15) 3 (20)
HCV co-infection (%)b 0.722
Yes 3 (15) 2 (13)
AIDS diagnosisb (%) (yes) 5 (25) 9 (60) 0.079
Time since first HIV Ab+, years (IQR)a 5 (5–7) 5 (3–7) 0.552
CD4 T-cell count (IQR)a
Nadir (n) 97 (42–230) 94 (26–124) 0.342
Time of analysis (n) 451 (404–585) 237 (164–299) <0.0001
HIV-RNA Log cp/mL (IQR)a at time of analysis 1.59 (1.59–1.59) 1.59 (1.59–1.59) 0.901
Low-level residual viremia HIV-RNA, cp/ml 20 (14–21) 20 (17–28) 0.321
cART duration, years (IQR)a 4.5 (3–5) 5 (3–6) 0.444
cART regimen (%)b 0.112
NRTI + PI 11 (55) 13 (86)
NRTI + NNRTI 7 (35) 1 (7)
Others 2 (10) 1 (7)
Plasma LPS, pg/mL (IQR)a 146 (75–264) 235 (108–258) 0.447
Plasma sCD14, μg/mL (IQR)a 6.36 (3.5–7.98) 4.23 (2.84–5.99) 0.139
Toll-like receptor (TLR) 4+ CD14+, % (IQR) 79.5 (62.8–86.1) 77.7 (44.3–90.5) 0.680
TLR8+ CD14+, % (IQR) 84.9 (69.7–93.8) 80.2 (76.1–87.8) 0.770
CD45RA+ CCR7+ CD4+ (%) (IQR) 3.4 (2.4–53.3) 2.4 (0.7–7.7) 0.231
CD45RA− CCR7+ CD4+ (%) (IQR) 3.7 (1.5–18.8) 2.5 (1.8–4.4) 0.536
CD45RA− CCR7− CD4+ (%) (IQR) 42.1 (13.8–45.7) 58.8 (42.3–67.5) 0.107
CD45RA+ CCR7− CD4+ (%) (IQR) 23.1 (4.3–53.2) 35.5 (26.8–47.4) 0.649
CD45RA+ CCR7+ CD8+ (%) (IQR) 6.3 (2–37.3) 5.2 (2.9–10.6) 0.837
CD45RA− CCR7+ CD8+ (%) (IQR) 3.8 (0.5–6.9) 1.7 (0.5–6.8) 0.620
CD45RA− CCR7− CD8+ (%) (IQR) 36.2 (9.7–54.1) 42.5 (16.5–58.4) 0.649
CD45RA+ CCR7− CD8+ (%) (IQR) 42.6 (26–56.2) 40.4 (24.7–55.3) 0.901
aData are median (IQR). IQR, interquartile range; statistical analyses: Mann–Whitney U Test.
bData are n (%), statistical analyses: Pearson chi squared or Fisher exact test; FRs: full responders (CD4 ≥ 350/mmc; HIV-RNA < 40 cp/mL); INRs: immunological non-responders 
(CD4 < 350/mmc; HIV-RNA < 40 cp/mL).
IDU, intravenous drug users; LPS, lipopolysaccharide; cART, combination of antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; NNRTI, 
non-nucleoside reverse transcriptase inhibitor.
Statistically significant p values (p < 0.05) are highlighted in bold font.
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mRNA Expression of Genes Involved in the  
TLR-Mediated Pathway
To further investigate the effect of TLR stimulation on PBMCs, 
we next measured gene transcription and cytokine/chemokine 
response following exposure to the representative TLR4 and 
TLR7/8 agonists LPS and ssRNA, respectively. We first screened 
84 genes involved in the TLR-activation pathway by real-time 
PCR array in PBMCs from untreated and treated HIV+ patients 
(FRs and INRs) and HIV-negative controls.
In cART-treated patients, LPS stimulation resulted in a mod-
est upregulation of mRNA transcription of TLR2 and TLR7 that 
was not seen in untreated HIV+ patients (Figure 3A), of genes 
involved in the pathogen-specific response (CD14, CLEC4E, 
PTGS2), and pro-inflammatory cytokines IL-1α, IL-6, and CSF3 
(Figure  3B). Interestingly, we observed an upregulation of the 
type I interferon genes (indicated by the arrows) in both HIV+ 
untreated and cART group compared to HIV-uninfected controls 
(Figure 3B).
Viral (ssRNA) stimulation induced a more potent upregula-
tion of TLR-activation pathway in HIV+ subjects as compared 
to uninfected controls (Figures 3C,D). HIV+ untreated subjects 
showed highest transcription of genes that modulate NFκB 
activity (IRAK2, NFKBIA, RIPK2, TBK1; Figure  3C), as well 
as pro-inflammatory cytokines/chemokines (CSF3, CXCL-10, 
IFN-γ, IL-1a, IL-1b, IL-6, IL-8, TNF-α; Figure 3D). cART group 
upregulated mRNA specific for CCL2, CSF2, and type I interfer-
ons (Figure 3D).
Upon a comparative analysis of treated individuals with differ-
ent response to cART, INRs presented higher constitutive mRNA 
expression levels (up to 20-fold) of effector molecules, such as 
FigUre 1 | In vitro toll-like receptor (Tlr) challenge on PBMcs: cD4 and cD8 T-cell activation, proliferation, and apoptosis. Data shown as a fold 
change: (stimulated percentage value)/(unstimulated percentage value). *indicates which comparison is the most significant (a) No upregulation of HLA-DR on CD4 
T-cells in all the three study groups following TLR challenge [lipopolysaccharide (LPS) p = 0.754; lipoteichoic acid (LTA) p = 0.945; peptidoglycan (PGN) p = 0.739; 
ssRNA p = 0.623; IFNγ p = 0.396; aCD3/CD28 p < 0.0001]. (B) Significant increase of CD38 + CD8 T-cell upon viral challenge alone in combination antiretroviral 
therapy group (LPS p = 0.081; LTA p = 0.587; PGN p = 0.360; ssRNA p = 0.044; IFNγ p = 0.764; aCD3/CD28 p = 0.304). (c,D) No differences in the proportion 
of Ki67 + CD4 T-cells (LPS p = 0.193; LTA p = 0.083; PGN p = 0.149; ssRNA p = 0.358; IFNγ p = 0.762; aCD3/CD28 p = 0.024) and Ki67 + CD8 T-cells following 
the exposure to TLR ligands (LPS p = 0.609; LTA p = 0.549; PGN p = 0.317; ssRNA p = 0.237; IFNγ p = 0.507; aCD3/CD28 p = 0.069). (e,F) No changes in 
pro-apoptotic Annexin V + CD4 (LPS p = 0.268; LTA p = 0.638; PGN p = 0.672; ssRNA p = 0.685; IFNγ p = 0.491; aCD3/CD28 p = 0.672) and CD8 (LPS 
p = 0.606; LTA p = 0.503; PGN p = 0.149; ssRNA p = 0.335; IFNγ p = 0.251; aCD3/CD28 p = 0.038) T-cells.
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CCL2, CSF2, CSF3, CXCL10, IFN-γ, IL1-a, IL-1b, IL-6, IL-8, and 
of genes involved in the pathogen-specific response (CLEC4E, 
HSPA1A, CD80, TLR3) (Figure 4A).
Both INRs and FRs failed to show a substantial upregulation 
of genes involved in the TLR downstream pathway upon LPS and 
ssRNA exposure (Figures 4B,C).
Interestingly, LPS exposure resulted in the upregulation of IL-1a, 
IL-6, and IL-8 in FRs alone (Figure 4D). Similarly, FRs were more 
responsive to ssRNA challenge (IFN-γ, IL-6, CSF2, and CSF3), 
except for type I interferons, which were higher in INRs (Figure 4E).
These data suggest a hyper-responsiveness to viral stimulation 
in both untreated and cART-treated HIV-infected subjects, con-
firming ssRNA as a potent immune activator in the setting of HIV 
infection. These results also suggest that despite an higher basal 
expression of genes involved in the TLR pathway, INRs are less 
responsive to TLR-specific stimulation and show upregulation of 
only type I IFNs following microbial challenge.
Cytokine/Chemokine Release in Supernatants
Last, we assessed cytokine/chemokine levels in LPS/ssRNA-
stimulated PBMC supernatants in a subset of 5 HIV-neg, 5 HIV+ 
untreated, and 11 HIV+ cART (5 INRs and 6 FRs), as proof of 
concept to be further investigated in larger cohorts (Figure 5).
Interestingly, in response to LPS, PBMCs from untreated 
HIV+ patients produced significantly higher IL-23 (p = 0.016) 
compared with cART-treated group, whereas PBMCs from 
cART-treated patients released higher TNF-α, IL-6, IL-1b, and 
CCL-20 as compared to untreated patients, however, lower than 
FigUre 2 | In vitro toll-like receptor (Tlr) challenge on PBMcs: cD4 and cD8 T-cell activation, proliferation, and apoptosis in Full responders (Frs) 
and immunological non-responders (inrs). Data shown as a fold change: (stimulated percentage value)/(unstimulated percentage value). (a) No upregulation 
of HLA-DR on CD4 T-cell following TLR stimulation between FRs and INRs [lipopolysaccharide (LPS) p = 0.300; lipoteichoic acid (LTA) p = 0.271; peptidoglycan 
(PGN) p = 0.258; ssRNA p = 0.683; IFNγ p = 0.287; aCD3/CD28 p = 0.975]. (B) No differences in CD38 + CD8 T-cell, according to the degree of immune recovery 
(LPS p = 0.141; LTA p = 0.091; PGN p = 0.573; ssRNA p = 0.442; IFNγ p = 0.271; aCD3/CD28 p = 0.257). (c) Gating strategy for Ki67 measurement in both CD4 
and CD8 T-cell subset before and after TLR stimulation (flow cytometry). (D,e) No changes in the proportion of Ki67 + CD4 T-cells (LPS p = 0.271; lipoteichoic acid 
(LTA) p = 0.240; PGN p = 0.896; ssRNA p = 0.798; IFNγ p = 0.267; aCD3/CD28 p = 0.183) and Ki67 + CD8 T-cells following the exposure to TLR ligands (LPS 
p = 0.671; LTA p = 0.741; PGN p = 0.403; ssRNA p = 0.471; IFNγ p = 0.182; aCD3/CD28 p = 0.929). (F,g) No changes in pro-apoptotic Annexin V + CD4 (LPS 
p = 0.182; LTA p = 0.237; PGN p = 0.387; ssRNA p = 0.669; IFNγ p = 0.963; aCD3/CD28 p = 0.079) and CD8 (LPS p = 0.661; LTA p = 0.905; PGN p = 0.546; 
ssRNA p = 0.813; IFNγ p = 0.370; aCD3/CD28 p = 0.842) T-cells.
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FigUre 3 | In vitro toll-like receptor (Tlr) challenge on PBMcs: mrna expression of genes involved in the Tlr pathway. TLR signaling pathway mRNA 
expression in HIV-negative healthy controls (white bars), HIV + untreated subjects (gray bars), and HIV + combination antiretroviral therapy (cART) subjects (black 
bars) for TLR4 and TLR 7/8 stimulation with lipopolysaccharide (LPS) and ssRNA respectively. (a,B) Modest upregulation of TLR2, TLR7, CD14, CLE4E, PTGS2, 
and IL-1α mRNA in HIV + cART patients alone following LPS stimulation. Upregulation of the type I interferon genes (indicated by the arrows) in both treated and 
untreated HIV-infected patients versus HIV-neg controls. (c,D) Higher transcription of IRAK2, NFKBIA, RIPK2, TBK1, CSF3, CXCL-10, IFN-γ, IL-1α, IL-1b, IL-6, IL-8, 
and TNF-α in untreated HIV+, following viral challenge. Upregulation of CCL2, CSF2, and type I interferons mRNA in cART-treated HIV+ subjects.
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uninfected controls (TNF-α: p = 0.014; IL-6: p = 0.034; IL-1b: 
p = 0.330; CCL-20: p = 0.093; Figure 5A).
Viral stimulation accounted for greater release of cytokines/
chemokines in all the study groups. In particular, upon ssRNA 
exposure PBMCs from both treated and untreated HIV-infected 
subjects produced highest CD14 (p =  0.014), whereas HIV+ 
untreated patients released highest IL-23 (p = 0.0008) (Figure 5B). 
HIV+ cART-treated patients tended to release higher TNF-α, 
IFN-γ, IL-6, and CCL-20 versus untreated patients, however, 
lower than uninfected controls (TNF-α: p = 0.015; IL-6: p = 0.067; 
IFN-γ: p = 0.164; CCL-20: p = 0.113; Figure 5B).
However, when we stratified HIV+ cART patients according 
to immune recovery degree, there were no significant differences 
upon LPS and ssRNA exposure between FRs and INRs (Figure 6).
effect of Tlr stimulation on MDMs:  
hla-Dr/cD69 cell-surface expression 
and cytokine/chemokine release
Because our data on PBMC TLR challenge in HIV-infected 
patients failed to demonstrate major effects on the T-lymphocyte 
compartment, in the face of different patterns of cytokine/
chemokine production according to presence or absence of 
therapy, we next sought to explore TLR challenge on an in vitro 
MDM system.
We first assessed the membrane expression of HLA-DR 
receptor. As expected, both treated and untreated HIV+ subjects 
consistently showed lower HLA-DR expression on MDM as 
compared to HIV-uninfected controls (Figure 7A).
We then studied MDM responsiveness to TLR challenge 
by the cell-surface expression of the activation marker CD69. 
Interestingly, in untreated HIV+ patients ssRNA stimulation was 
less efficient in increasing the proportion of CD69 + MDM as 
compared to HIV+ treated patients and HIV-negative controls 
(p = 0.015). No differences in both HLA-DR+ and CD69+ MDM 
were shown between INRs and FRs (data not shown).
To further investigate the effect of TLR stimulation on MDMs, 
cytokine and chemokine release was measured in supernatants 
following exposure to LPS and ssRNA (Figures 7B,C).
Interestingly, upon bacterial stimulation, MDMs of untreated 
HIV+ were characterized by lowest cytokine/chemokine release 
(<4-fold) (Figure  7B). Conversely, in cART-treated patients, 
FigUre 4 | In vitro toll-like receptor (Tlr) challenge on PBMcs: mrna expression of genes involved in the Tlr pathway in Full responders (Frs) 
and immunological non-responders (inrs). TLR signaling pathway mRNA expression in HIV + combination antiretroviral therapy (cART) FRs (white bars) and 
HIV + cART INRs (black bars) for TLR4 and TLR 7/8 stimulation with lipopolysaccharide (LPS) and ssRNA, respectively. (a) Higher constitutive mRNA (up to 20-fold) 
of CCL2, CSF2, CSF3, CXCL10, IFNγ, IL1α, IL1b, IL6, IL8, CLEC4E, HSPA1A, CD80, and TLR3, in INRs as compared to FRs. (B,c) No effect on TLR downstream 
pathway after LPS and ssRNA stimulation. (D) Upregulation of IL-1α, IL-6, and IL-8 in FRs alone following LPS stimulation. (e) Higher mRNA transcription of IFN-γ, 
IL-6, CSF2, and CSF3 in FRs and higher type I interferons in INRs after ssRNA stimulation.
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LPS challenge raised TNF-α and IL-6 release despite not reach-
ing statistical significance in comparison to the other groups 
(Figure 7B).
Viral stimulation accounted for greater cytokine/chemokine 
release, particularly TNF-α and IL-6 in both treated and untreated 
HIV+ subjects compared to HIV− controls (Figure 7C). No sig-
nificant differences were found within cART patients following 
FRs and INRs categorization (data not shown).
Taken together, these findings point to ex vivo viral challenge 
as a more potent pro-inflammatory/activatory stimulus in both 
untreated and treated HIV when compared to bacterial stimulus. 
In particular, LPS failed to elicit strong immune responses in 
untreated individuals, suggesting tolerance to already elevated 
endotoxemia in these patients.
DiscUssiOn
Our report sought to help elucidate the role of signaling via TLR 
pathways in sustaining immune activation in cART-treated HIV-
infected patients as compared to both HIV+ untreated patients 
and uninfected controls.
Despite complete or near-complete suppression of HIV repli-
cation with cART, chronic inflammation and immune activation 
persist indefinitely (54, 55) and have been implicated in the 
pathogenesis of both impaired immunological recovery (1–4) 
and clinical outcome (8, 9, 56, 57).
Therefore, dissecting the mechanisms that sustain such 
persistent chronic immune activation and its relationship with 
poor immune reconstitution will provide important avenues to 
improve disease management in HIV-infected cART-treated 
individuals.
Prior in  vivo studies have shown an association between 
microbial translocation, immune activation, and inadequate 
CD4 recovery on cART (32, 58). Along the same line, in  vitro 
research has shown a direct link between microbial stimulation 
and immune activation in both HIV-uninfected (12, 37–39, 53) 
and HIV-infected untreated individuals through TLR signaling 
(18, 31, 33, 50, 59–61).
We, first, assessed the response of PBMCs to bacterial and 
viral TLR stimulation in all study groups. Upon bacterial 
(LPS) stimulation, PBMCs from both treated and untreated 
patients displayed an overall feeble cytokine release, possibly 
reflecting tolerance to the highest levels of circulating LPS or 
recent in vivo activation. PBMCs from cART patients featured 
greater production of cytokines/chemokines directly involved 
in inflammation, such as TNF-α, IL-6, IL-1b, and CCL-20 
(yet lower than healthy HIV-uninfected controls). Conversely, 
PBMCs from antiretroviral-naïve patients released highest 
FigUre 5 | In vitro toll-like receptor challenge on PBMcs: cytokine/chemokine release. 12 different analytes were measured from PBMCs supernatant of 5 
HIV-negative healthy controls (white bars), 5 HIV+ untreated subjects (gray bars), and 11 HIV + combination antiretroviral therapy (cART) subjects (black bars) 
following lipopolysaccharide (LPS) and ssRNA, respectively. The figure depicts only cytokines/chemokines with a detectable production following LPS (a) and 
ssRNA (B) stimulation. Data shown as a fold change: (LPS-/ssRNA-stimulated cytokine value)/(unstimulated cytokine value). (a) LPS: PBMCs from untreated HIV+ 
produced significantly highest IL-23 (p = 0.016); PBMCs from cART-treated released higher TNF-α (p = 0.014), IL-6 (p = 0.034), IL-1b, and CCL-20 (p = 0.093) 
versus HIV+ untreated, lower than HIV-neg controls. (B) ssRNA: PBMCs from both HIV+ untreated and cART produced highest CD14 (p = 0.014), whereas HIV+ 
untreated patients released highest IL-23 (p = 0.0008). HIV + cART-treated patients tended to release higher TNF-α (p = 0.015), IFN-γ (p = 0.164), IL-6 (p = 0.067), 
and CCL-20 (p = 0.113) versus HIV+ untreated patients, lower, however, than uninfected controls.
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FigUre 6 | In vitro toll-like receptor challenge on PBMcs: cytokine/chemokine release in Full responders (Frs) and immunological  
non-responders (inrs). The 25 different analytes were measured from PBMCs supernatant of 5 INR and 6 FR patients following lipopolysaccharide (LPS) and 
ssRNA stimulation, respectively. The figure depicts only cytokines/chemokines with a detectable production following LPS (a) and ssRNA (B) stimulation. Data 
shown as a fold change: (LPS-/ssRNA-stimulated cytokine value)/(unstimulated cytokine value). (a) Each plot represents one individual, with the donor number 
noted at the top. In particular patient#1 is representative of FR group, whereas patient#2 is representative of INR group. The limits of detection of each analyte are 
shown in gray bars. (B,c) Data shown as a fold change: (LPS-/ssRNA-stimulated cytokine value)/(unstimulated cytokine value). (B) No significant differences in 
cytokine released between FRs and INRs after LPS exposure. (c) No major differences in cytokine release after ssRNA exposure.
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FigUre 7 | In vitro toll-like receptor (Tlr) challenge on monocyte-derived macrophages (MDMs): hla-Dr expression and cytokine/chemokine 
release. (a) Lower constitutively and TLR-driven HLA-DR expression on MDM in untreated and combination antiretroviral therapy (cART)-treated HIV+ versus 
HIV− controls. (B,c) Data presented as fold change (stimulated/unstimulated condition). Luminex quantification of 12 different analytes from MDM supernatant of 5 
HIV-negative, 5 HIV+ untreated, and 5 HIV + cART subjects. (B) Feeble cytokine/chemokine release (<4-fold) from MDMs of untreated HIV+ after lipopolysaccharide 
(LPS) exposure. Higher TNF-α and IL-6 release in cART-treated patients following LPS challenge. (c) Higher cytokine/chemokine release, particularly TNF-α and IL-6 
in both treated and untreated HIV-infected patients as compared to HIV− controls following ssRNA stimulation.
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IL-23, a finding consistent with previous research and that has 
been correlated with systemic immune activation and gut dam-
age (36, 62).
Similar findings were manifested in an experimental setting 
of TLR-stimulated MDMs from cART-treated patients, which 
displayed lowest HLA-DR expression and highest LPS-driven 
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release of pro-inflammatory TNF-α and IL-6, altogether indi-
cating severely impaired monocyte/macrophage function with 
a broader pro-inflammatory potential, reminiscent of what is 
observed in severe pro-inflammatory clinical settings (63).
Interestingly, in our patients’ cohort, none of the bacterial 
agonists that we tested and that mimic both Gram+ and Gram− 
bacteria (i.e., LPS, LTA, PGN) resulted in a significant expansion 
of activated, proliferating, apoptotic T-lymphocytes, confirming 
the modest effect of TLR stimulation alone in the direct activation 
of T-lymphocytes (37, 38).
We, next, evaluated the PBMC/MDM response to viral stimu-
lation, which proved a stronger pro-inflammatory challenge in 
HIV-infected individuals as a whole. Despite full HIV-viremia 
suppression, TLR7/8 stimulation, which has been shown to 
recognize HIV-1 ssRNA, resulted in high transcription of genes 
involved in the TLR pathway and pro-inflammatory cytokine/
chemokine release from PBMCs and MDMs of cART-treated 
patients, at levels not substantially lower than HIV+ untreated 
patients. Most interestingly, direct ssRNA stimulation resulted in 
a significant expansion of activated CD38+ CD8 T-cells uniquely 
in cART patients.
Two major observations stem from the findings of this 
first part of the study: (i) viral stimulation appears a stronger 
stimulus than LPS, clearly pointing to HIV itself, or its compo-
nents, as a major source of innate immune activation even in 
the presence of virally suppressive cART, as also suggested by 
the demonstration in our patients of low-level residual viremia, 
at levels below the threshold of commercially available assays. 
(ii) Bacterial stimulation seems to exert a superior effect on 
monocyte/macrophage activation from cART-treated versus 
untreated patients, with no major effect on T-lymphocytes, 
pointing to translocating bacteria as selective stimulus to innate 
immunity during virally suppressive cART. Because clinical and 
translational research strongly suggests that chronic activation 
of innate immunity drives morbidity/mortality in treated HIV 
(64–68), our data provide in  vitro evidence (tested in culture 
from both whole PBMCs and MDMs) of how monocyte/mac-
rophages from cART patients might be preferentially activated 
by circulating bacterial products. Given the persistence of gut 
damage and microbial translocation during cART (9, 25, 26, 
29, 69), we hereby provide an indication of how the systemic 
exposure to bacterial TLR agonists translocated from a dam-
aged gut may contribute to excessive morbidity/mortality in 
these patients.
In the second part of our research, we restricted the analysis 
to cART-treated patients with different CD4 recovery, with the 
ultimate aim to dissect possible role of TLR signaling in the 
inadequate CD4 reconstitution on cART. Despite our approach 
of gene expression analysis does not capture a statistical sig-
nificance also due to the small number of patients investigated, 
PBMCs from INRs seem to display greater constitutive mRNA 
expression of genes involved in the TLR-mediated pathway, yet 
upregulated only type I IFN genes following stimulation with 
TLR agonists. In contrast, TLR engagement in FRs seemed to 
result in the broad induction of genes involved in innate and 
adaptive immune responses. Taken together, these findings may 
suggest less efficient TLR-mediated signaling following exposure 
to TLR ligands in individuals with poor immune recovery after 
cART, which may be explained by tolerance (70, 71) or achieve-
ment of maximal transcription levels. Furthermore, by suggesting 
higher transcription of type I IFN genes in INRs in response to 
viral challenge, our findings support further investigation of IFN/
interferon-stimulated genes pathways, both of which have been 
proven to accelerate HIV/SIV pathogenesis, according to the 
response to cART (72–74).
In addition, while our failure to find any differences between 
INRs and FRs in cytokine/chemokine release by PBMCs and 
T-cell activation might be due to the limited number of patients 
analyzed, it may also reflect the mixed contribution of TLR-
dependent and -independent pathways in supporting immune 
activation and inflammation.
Several caveats in the experimental design of the present 
study must be acknowledged including prolonged cell culture, 
which might have selected the strongest and most functional 
MDMs, and the lack of cocultures of single APCs (macrophages, 
dendritic, or B cells) and CD3+ T-cell subpopulation, which 
could have more precisely highlighted the contribution to TLR 
signaling pathways of each cell subset. Despite these limita-
tions, we show an impairment in TLR pathway of HIV-infected 
subjects that seems to persist upon cART long-term treatment 
with possible differences according to the degree of immune 
recovery. Bacterial TLR agonists have little effect on MDM-
mediated signaling, implying a role of other cell populations 
in inducing T-cell activation in this setting. Viral components 
nonetheless appear to affect MDM activation in all subjects 
receiving cART.
Taken together, our findings indicate systemic exposure to 
microbial TLR agonists as driver of immune activation in treated 
HIV and suggest that the contribution of persistent (low-level) 
viral exposure might overweight microbial exposure. In this 
view, our research may partially facilitate an explanation of why 
rifaximin or sevelamer, by antagonizing microbial bioproducts 
in the systemic circulation, may not lower T-cell activation in 
HIV-infected humans (75, 76), despite the intriguing results 
obtained in the animal model (77). The research may also suggest 
the need for a more comprehensive elucidation of the role of the 
TLR system in promoting HIV-driven immune hyperactivation. 
Challenges include a broad analysis of the differential role of 
TLR-mediated signaling and the exact set of regulators of TLR 
pathway (e.g., miRNAs), as well as genes/molecules activated 
upon TLR stimulation within different cell subpopulations and 
their downstream effector functions. Unraveling the role of 
the TLR pathway(s) in orchestrating immune activation in the 
context of treated infection is mandatory for its exploitation 
for therapeutic purposes. Finally, the observation of cytokine 
release from MDMs of HIV-infected subjects pose monocytes/
macrophages as an important source of pro-inflammatory 
mediators, which have been associated with cardiovascular 
disease, HIV-associated neurocognitive development, and innate 
immune aging (78).
Thus, therapeutically targeting sources and pathways of 
monocyte activation could be a useful strategy to limit immune 
activation associated with the premature development of age-
related diseases for HIV-infected persons treated with cART.
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